

The diagnosis was based on enzyme activity assays in fibroblasts and sequencing of the *ALDH3A2* gene. Both patients were homozygous for the previously described variant c.471+1delG (NM\_000382.2).

The family segregation analysis confirmed that both parents were carriers of the variant.

As of June 2020, there were 280 reported variants of the *ALDH3A2* gene in 182 individuals with Sjögren-Larsson syndrome (Leiden Open Variation Database [LOVD], PubMed). Some, like c.471+1delG, detected in patients 2 and 3, have been described in many European families. However, the variants detected in patient 1 were novel.<sup>5</sup>

A previous review of cases reported in Spain identified 4 cases diagnosed in adulthood after detection of the characteristic ocular or cutaneous lesions, and only 1 diagnosed in childhood.<sup>6</sup>

The c.86\_96del variant produces a shift in the reading frame and results in a truncated protein. However, the presence of another start codon downstream suggests the possibility of a protein missing the first 32 amino acids (of the 508 of the full protein) that could maintain some residual activity and result in an attenuated phenotype.

We believe that it is important to be aware of the association of congenital ichthyosis with neurologic impairment as one of the known neuroichthyotic syndromes and of the presence of carriers of these variants in Spain to facilitate early diagnosis and the establishment of an accurate phenotype/genotype correlation. Patient 1, who had a deletion and a variant that had not been previously described presented with more severe axial hypotonia and milder ichthyosis compared to patients 2 and 3, who had a previously described variant.

## References

1. Fuijkschot J, Theelen T, Seyger MMB, van der Graaf M, de Groot IJM, Wevers RA, et al. Sjögren-Larsson syn-

- drome in clinical practice. *J Inherit Metab Dis.* 2012;35:955–62.
2. Rizzo WB, Carney G. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (*ALDH3A2*). *Hum Mutat.* 2005;26:1–10.
3. Rizzo WB, Carney G, Lin Z. The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. *Am J Hum Genet.* 1999;65:1547–60.
4. Rizzo W, Jenkins S, Boucher P. Recognition and diagnosis of neuro-ichthyotic Syndromes. *Semin Neurol.* 2012;32:075–84.
5. Weustenfeld M, Eidelpes R, Schmuth M, Rizzo W, Zschocke J, Keller M. Genotype and phenotype variability in Sjogren Larsson syndrome. *Hum Mutat.* 2019;40:177–86.
6. Mora-López F, Vilches-Moreno M, Marín-Iglesias R. Nueva mutación en el gen *ALDH3A2* en un niño con síndrome de Sjogren-Larsson. *Rev Neurol.* 2018;67:415–6.

Cristina Villar-Vera<sup>a,\*</sup>, Ana Cuesta Peredo<sup>b</sup>, Lucía Monfort-Belenguer<sup>a</sup>, María Rosario Abellán Sanchez<sup>c</sup>, Cecilia Martínez-Costa<sup>d</sup>

<sup>a</sup> *Unidad de Neuropediatría, Servicio de Pediatría, Hospital Clínico Universitario de Valencia, Valencia, Spain*

<sup>b</sup> *Laboratorio de Bioquímica y Patología Molecular, Hospital Clínico Universitario de Valencia, Valencia, Spain*

<sup>c</sup> *Unidad de Genotipado y Diagnóstico Genético, Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain*

<sup>d</sup> *Servicio de Pediatría, Hospital Clínico Universitario de Valencia, Valencia, Spain*

\* Corresponding author.

E-mail address: [crisvillarvera@gmail.com](mailto:crisvillarvera@gmail.com) (C. Villar-Vera).

<https://doi.org/10.1016/j.anpede.2020.07.019>  
2341-2879/ © 2021 Published by Elsevier España, S.L.U. on behalf of Asociación Española de Pediatría. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Antenatal hydronephrosis: Key sign for the diagnostic of a familial genetic disease<sup>☆</sup>



### Ectasia piélica antenatal: signo guía para el diagnóstico familiar de una enfermedad genética

Dear Editor:

Hepatocyte nuclear factor-1 beta (*HNF-1β*; genetic locus *17q12*) is involved in the development of several tissues in the organogenesis of the pancreas, liver and genitourinary system. Maturity-onset diabetes of the young (*MODY*)

and renal cysts<sup>1</sup> are the diseases in which the role of *HNF-1β* is well known, but its involvement in other congenital anomalies of the urinary tract is not well understood. These disorders follow an autosomal dominant pattern of inheritance. We present the case of a family affected by a variant of the *HNF1B* gene in which the index case was an infant that received an antenatal diagnosis of hydronephrosis manifesting with renal pelvis dilatation.

The patient was an infant aged 12 months followed up from month 1 post birth due to antenatal diagnosis of hydronephrosis with dilatation of the left renal pelvis and calyces categorised as grade 3–4 (Society for Fetal Urology classification).<sup>2</sup> The postnatal follow-up ultrasound scan confirmed the dilatation of the renal pelvis and calyces, but also detected an abnormally small left kidney (2.5 SD below mean) with 2 cortical cysts, with a normal contralateral kidney. The personal history was otherwise unremarkable. The voiding cystourethrogram was normal and the <sup>99m</sup>Tc-MAG3 diuretic renogram found normal function in both kidneys and no evidence of obstruction. The follow-up ultrasound scan at 1 year post birth evinced kidneys of normal size other than the left-sided dilatation, but with bilateral hypere-

<sup>☆</sup> Please cite this article as: Alarcón-Alacio MT, Penela-Vélez de Guevara MT, Ballesteros-García MM, Rivero-Martín MJ. Ectasia piélica antenatal: signo guía para el diagnóstico familiar de una enfermedad genética. *An Pediatr (Barc)*.2021;95:204–206.

**Table 1** Diseases presenting with renal cysts.<sup>1</sup>

Genetic	Non-genetic
<ul style="list-style-type: none"> <li>• Autosomal recessive polycystic kidney disease (ARPKD)</li> <li>• Autosomal dominant polycystic kidney disease (ADPKD)</li> <li>• Nephronophthisis</li> <li>• Medullary cystic kidney disease</li> <li>• DNF1β-related disease</li> <li>• Von Hippel-Lindau disease</li> <li>• Tuberous sclerosis complex</li> <li>• Renal cysts in malformation syndromes</li> </ul>	<p><i>Developmental anomalies</i></p> <p>Medullary sponge kidney</p> <p>Multicystic renal dysplasia</p> <p><i>Acquired diseases</i></p> <p>Acquired cystic kidney disease</p> <p>Simple renal cysts</p> <p>Multilocular renal cyst</p> <p>Hypokalaemic cystic disease</p>

**Table 2** HNF1B score.<sup>5</sup>

Family history	+ 2	
Hyperechogenic kidney <sup>a</sup>	+ 4	
Renal cysts <sup>a</sup>	+ 4	
Hypoplastic kidney <sup>a</sup>	+ 2	
Urinary tract malformation <sup>a</sup>	+ 1	HNF1B score < 8, NPV 99.4%
Polycystic kidney	+ 2	
Solitary kidney	+ 1	HNF1B score ≥ 8, Sen 98.2%, Spe 41.1%, PPV 19.8%
Hypomagnesemia	+ 2	
Hypokalaemia	+ 1	
Gout with early onset (<30 years)	+ 2	
MODY or pancreas hypoplasia	+ 4	
Genitourinary anomalies	+ 4	
Transaminase elevation	+ 2	

MODY, maturity-onset diabetes of the young; NPV, negative predictive value; PPV, positive predictive value; Sen, sensitivity; Spe, specificity.

<sup>a</sup> If bilateral: x 2.

chogenicity and renal cysts, while laboratory tests detected an elevated creatinine level (0.6 mg/dL) and a decreased glomerular filtration rate (GFR, Schwartz formula [2009]: 52.9 mL/min/1.73 m<sup>2</sup>). The only relevant finding of the family history was the presence of type 1 diabetes (T1D) in the father and paternal grandfather. A sister aged 3 years was healthy with normal renal sonographic features. We reviewed the medical history of the father and found that at the time of diagnosis of T1D at age 16 years, the ultrasound examination of the kidneys had found bilateral hyperechogenicity and bilateral renal cysts. Furthermore, 5 years after the diagnosis of T1D, the father had received a diagnosis of diabetic nephropathy with stage 3A chronic kidney disease (CKD) that was atypical due to the absence of albuminuria (category A1) and to adequate metabolic control (glycated haemoglobin <6.5%). Also salient was the presence of high creatinine levels from age 10 years (1.1 to 1.6 mg/dL) predating the diagnosis of DM1. The clinical picture of the grandfather was similar to that of the father. Given the suspicion of renal cysts and diabetes syndrome in the family, we ordered testing of the *HNF1B* gene in the index patient, which identified a heterozygous variant (change in *HNF1B*, NM\_000458.2: c.554+3\_554+6del). Genetic testing was then performed in the father, with detection of the same mutation. At present, the patient is aged 25 months and has CKD stage G3A A1 (GFR, Schwartz formula [2009], 59 mL/min/1.73 m<sup>2</sup> and cystatin c-Pottel

equation [2017], 52 mL/min/1.73 m<sup>2</sup>) with hyposthenuria in absence of the albuminuria, metabolic acidosis, electrolyte imbalance, hypomagnesaemia, hyperuricaemia or hypertransaminaemia characteristic of CKD. The patient is managed exclusively with dietary measures.

Changes in the *HNF1B* gene were responsible for the syndrome manifesting with renal cysts and diabetes, which would be categorised as an autosomal dominant tubulointerstitial kidney disease (Table 1).<sup>3</sup> These variants typically present with renal cysts and diabetes syndrome (MODY type 5), usually with postpubertal onset. The severity of renal involvement varies widely, ranging from foetal death due to prenatal kidney failure to normal renal function in adulthood, with no phenotype-genotype correlation.<sup>1,3</sup> They are also one of the most common causes of hyper-echoic kidneys in the foetus and the most frequently identified monogenic cause of congenital anomalies of the urinary tract (prevalence of 10% to 30% depending on the case series), and may manifest with renal agenesis, polycystic kidney, unilateral or bilateral renal dysplasia, renal ectopia, vesicoureteral reflux, pyeloureteral junction stenosis or hydronephrosis,<sup>4-6</sup> as occurred in our patient. Besides diabetes (including gestational diabetes), the most frequent extrarenal manifestations are hypomagnesemia, hypokalaemia, hyperuricemia, gout and transaminase elevation. Given that the initial presentation of a *HNF1B* variant may be a congenital anomaly of the kidney and urinary

tract (CAKUT) and that changes in this gene are among the most frequent causes of sonographic abnormalities in the antenatal period, recommendations have been published to determine the indication of testing of the *HNF1B* gene in patients with CAKUT based on a series of eligibility criteria (Table 2).<sup>4,5</sup> Awareness of this disease is important not only for the purpose of early diagnosis (to ensure adequate follow-up in these patients, improve long-term outcomes and slow down the progression of renal disease), but also to provide genetic counselling to affected families, which is particularly necessary in the case of *HNF1B* gene variants due to their broad phenotypic spectrum, since there may be individuals with onset of CKD in the first year of life whose parents have milder forms of disease, as was the case of the patient presented in this article.

## References

1. Iceta Lizarraga A, Barajas de Frutos D. Enfermedades quísticas renales. *Protoc Diagn Ter Pediatr*. 2014;1:191–206.
2. Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: Introduction to the system used by the society for fetal urology. *Pediatr Radiol*. 1993;23:478–80.
3. Ayasreh Fierro N, Miquel Rodríguez R, Matamala Gastrón A, Ars Criach E, Torra Balcells R. Revisión de la nefropatía tubulointersticial autosómica dominante. *Nefrología*. 2017;37:235–43.
4. Raaijmakers A, Corveleyn A, Devriendt K, Van Tienoven TP, Allegaert K, Van Dyck M, et al. Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. *Nephrol Dial Transplant*. 2015;30:835–42.
5. Faguer S, Chassaing N, Bandin F, Prouheze C, Garnier A, Casemayou A, et al. The HNF1B score is a simple tool to select patients for HNF1B gene analysis. *Kidney Int*. 2014;86:1007–15.
6. Ulinski T, Lescure S, Beaufils S, Guignon V, Decramer S, Morin D, et al. Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. *J Am Soc Nephrol*. 2006;17:497–503.

María Teresa Alarcón-Alacio\*,  
 María Teresa Penela-Vélez de Guevara,  
 María del Mar Ballesteros-García, María José Rivero-Martín  
*Hospital Universitario de Fuenlabrada, Madrid, Spain*

\* Corresponding author.

E-mail address: [terearc@hotmail.com](mailto:terearc@hotmail.com)  
 (M. T. Alarcón-Alacio).

<https://doi.org/10.1016/j.anpede.2021.03.004>  
 2341-2879/ © 2021 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).